Helsingborg, Sweden – June 10, 2020 – AQILION AB held its Annual General Meeting today on June 10, 2020, during which the Meeting resolved in accordance with the proposals set forth by the Board of Directors and the Nomination Committee. The complete details of the proposed resolutions can be found in the Notice to attend the Annual General Meeting.
Adoption of income statement and balance sheet, as well as allocation of result
The Annual General Meeting resolved to adopt the annual accounts with income statement and balance sheet for the 2019 financial year. The Meeting resolved that the entire amount at the disposal of the Meeting would be carried forward.
The Annual General Meeting resolved that no dividend would be paid for the 2019 financial year.
Discharge from liability
The Annual General Meeting resolved to discharge the Directors of the Board and the Chief Executive Officer from liability for the 2019 financial year.
The Nomination Committee for the 2020 Annual General Meeting of AQILION AB consisted of Lena Mårtensson (chair), Helena Arcombe, Clas Runnberg and Malin Ruijsenaars.
Determination of fees for the members of the Board of Directors and the auditors
The Annual General Meeting resolved to pay fees until the close of the next Annual General Meeting in the amount of SEK 210,000 to the Chairman of the Board and SEK 90,000 for each Director of the Board who is not employed by the company. Remuneration to the auditor will be paid on approved account.
Determination of the number of Board Members and election of the Board
The Meeting resolved that the Board will consist of five members without deputies. The following individuals were elected to serve on the Board until the next Annual General Meeting: Johan Lund (reelection), Marie Lidgard (reelection), Roland Andersson (reelection), Andreas Segerros (reelection) and Martin Olovsson (reelection). Johan Lund was elected to serve as Chairman of the Board. Jörgen Johnsson and Karin Wingstrad declined reelection.
Election of auditor
Mazars AB Helsingborg with authorized public accountant Andreas Brodström and Bertil Toresson as co-auditor were reelected to serve until the next Annual General Meeting.
Adoption of principles for appointing the Nomination Committee and the task of the Nomination Committee
The Annual General Meeting resolved in accordance with the Board’s proposal. The resolution on instructions for the Nomination Committee shall be in effect until such time that the Annual General Meeting decides otherwise.
Resolution on changing the form of business enterprise
The Annual General Meeting resolved to change the form of business enterprise from a private limited company to a public limited company.
Resolution to amend the Articles of Association
The Annual General Meeting resolved in accordance with the Board’s proposal to change the wording of paragraph 1 of the Articles of Association from “The company name” to “The company’s business name.” The Annual General Meeting also resolved to amend the Articles of Association in paragraph 6 Board of Directors and auditors, paragraph 7 Notice, paragraph 8 General Meeting and paragraph 13 Authorization for the Board of Directors to resolve on the issuance of shares, convertibles and/or warrants.
For more information, please contact
CEO, AQILION AB
+46 (0)70 261 4575
About AQILION AB
Aqilion is a Swedish life science company that identifies unique ideas that have the potential to become new medications and refines them into commercially interesting projects. Our projects are based on solid scientific grounds where we can clearly understand the underlying biology, clinical relevance and patient benefit. We focus on indications within inflammation at the interface of oncology and immunology, where we see a great future need, good potential for innovation and a clear interest in the market. Our customers represent the next step in the care chain: the pharmaceutical and biotech industries. Aqilion has its headquarters in Helsingborg. Please visit www.aqilion.com.